KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Accounts Payables (2016 - 2025)

Historic Accounts Payables for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $33.6 billion.

  • AbbVie's Accounts Payables rose 1025.51% to $33.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 billion, marking a year-over-year increase of 1025.51%. This contributed to the annual value of $31.9 billion for FY2024, which is 422.51% up from last year.
  • According to the latest figures from Q3 2025, AbbVie's Accounts Payables is $33.6 billion, which was up 1025.51% from $32.2 billion recorded in Q2 2025.
  • In the past 5 years, AbbVie's Accounts Payables registered a high of $33.6 billion during Q3 2025, and its lowest value of $20.6 billion during Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $27.0 billion (2023), whereas its average is $27.0 billion.
  • In the last 5 years, AbbVie's Accounts Payables surged by 6212.13% in 2021 and then tumbled by 90.98% in 2025.
  • Quarter analysis of 5 years shows AbbVie's Accounts Payables stood at $22.7 billion in 2021, then rose by 11.91% to $25.4 billion in 2022, then grew by 20.66% to $30.6 billion in 2023, then grew by 4.23% to $31.9 billion in 2024, then grew by 5.24% to $33.6 billion in 2025.
  • Its Accounts Payables stands at $33.6 billion for Q3 2025, versus $32.2 billion for Q2 2025 and $31.0 billion for Q1 2025.